Spectrum Healthcare Partners (SHCP), a multispeciality, physician-owned healthcare practice, has selected the Concentriq Dx software platform from digital and computational pathology solutions provider Proscia.
SHCP intends to implement Proscia’s advanced digital pathology platform to modernise its operations and increase access to high-quality diagnostic services across the states of Maine and New Hampshire in the US.
Spectrum Healthcare Partners Pathology Division managing director Bilal Ahmad said: “Concentriq Dx is critical to decentralising our diagnostic services. It will enable us to seamlessly transition to digital pathology at scale so that we can reimagine our day-to-day operations beyond the confines of our physical laboratory spaces.”
The Concentriq Dx platform is designed to drive diagnostic workflows for laboratory networks and offers interoperability with scanners and image analysis applications.
Furthermore, the platform streamlines collaboration by allowing remote image viewing, thus providing subspecialist experts with faster and broader access.
Proscia CEO David West said: “Our organisations share a strong commitment to the patient, and we are thrilled that SHCP sees the value of modern digital pathology in democratising diagnosis and helping to improve treatment decisions.”
Proscia said that the platform, which is CE-marked under the in vitro diagnostic regulation (IVDR), helps to realise pathology’s artificial intelligence (AI)-powered future to address growing needs.
Spectrum Healthcare comprises 200 physicians who practice in the areas of anesthesiology, orthopaedics, pathology, radiation oncology, radiology, and vascular and interventional radiology.
Concentriq Dx has been made available by the firm for primary diagnosis in the US during the Covid-19 public health emergency.